Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
College student released after Texas military post lockdown
24 Nov 2014 at 3:24pm
By Jim Forsyth SAN ANTONIO (Reuters) - A male college student was released on Monday after being taken into custody for driving an unauthorized vehicle onto San Antonio's Fort Sam Houston military base on Sunday night, sparking a lockdown and a full security alert, officials said. The San Antonio-area man, who has not been identified, posed no security risk, military officials said without offering further details. The suspect was alone in his car when military police pulled him over after a brief pursuit. ...
Mali confirms eighth Ebola case, monitoring 271 people
24 Nov 2014 at 3:19pm
BAMAKO (Reuters) - Mali said on Monday that another person had tested positive for the Ebola virus, bringing the total number of cases in the West African nation to eight. Mali is the sixth West African country to be hit by the worst outbreak on record of deadly haemorrhagic fever that has killed some 5,459 since the first case was recorded early this year in neighboring Guinea. The Malian government did not provide further details about the new case and how the person contracted the disease, but it came after another case was confirmed on Saturday. ...
Iran Mourns Lost Youth in Thousands
24 Nov 2014 at 1:58pm
The coffin holding Morteza Pashaei's body was carried through a large crowd on Sunday in Tehran. Photo Credit: Saeed Faramarzi/Nasimonlinehttp://www.nasimonline.ir/detail/Photo/949475/238For the first time in nearly three decades since the 1979 Islamic Revolution, the Iranian people and the government were in unison to mourn a pop singer's...
NYC doctor known for radio ads settles Medicare fraud case
24 Nov 2014 at 1:57pm
By Jonathan Stempel NEW YORK (Reuters) - Gilbert Lederman, a former director of radiation oncology at Staten Island University Hospital, agreed to pay $2.35 million to resolve claims that he defrauded Medicare by seeking reimbursement for an experimental cancer treatment he claimed to have pioneered in the United States. Lederman, whose radio ads featuring his distinctive monotone have been a staple of New York airwaves, denied wrongdoing in agreeing to settle the 10-year-old False Claims Act lawsuit. The settlement was made public on Monday by U.S. ...
Mali confirms eighth Ebola case
24 Nov 2014 at 1:57pm
BAMAKO, Mali (AP) ? Mali has confirmed a new case of Ebola, bringing to eight the number of people who have fallen ill with the deadly disease in the West African country.
Studies examine U.S. meals in schools
24 Nov 2014 at 1:55pm
By Andrew M. Seaman (Reuters Health) ? School meals may be beneficial to students and be better in nutritional quality than meals brought from home, suggests two new studies looking at U.S. students. Elementary school students are more likely to eat breakfast at school if it?s provided in the classroom, compared to another location, researchers write in JAMA Pediatrics. Additionally, breakfast in the classroom was tied to better school attendance. ...
For rural veterans with PTSD, telemedicine may help
24 Nov 2014 at 1:12pm
By Kathryn Doyle (Reuters Health) ? For the many veterans with post-traumatic stress disorder (PTSD) who don?t have access to a trained mental health care team, connecting with such a team remotely by phone and video chats may help, a new study suggests. At least 500,000 veterans in the Veterans Health Administration (VHA) system, or nearly 10 percent of the VHA population, were diagnosed with PTSD in 2012, the researchers write in JAMA Psychiatry. ...
Confessions of a Reformed Dieting Junkie
24 Nov 2014 at 12:56pm
My life revolves around healthy food. I was born into a household that believed in natural health, where a vinegar compress was considered to be the best fever remedy, and private yoga classes were hosted in our living room long before yoga studios adorned every street corner. When I grew to adolescence I took things further and began focusing...
Helmets, engine size important in child deaths on ATVs
24 Nov 2014 at 12:38pm
By Kathryn Doyle (Reuters Health) - Child deaths from crashes of all-terrain vehicles (ATVs), which dipped after 1985, began to climb again around 2001, and 12- to 15-year-olds accounted for more than half of all fatalities, according to a new study of Consumer Product Safety Commission data. The data include kids killed at ages six through age 18, but deaths in each age group were influenced by different risks, the authors write. ...
FBI says 27 U.S. law enforcement died during crimes in 2013; sharp drop
24 Nov 2014 at 12:35pm
WASHINGTON (Reuters) - The FBI reported on Monday that 76 law enforcement officers in the United States died last year while on duty, including 27 during criminal acts, a sharp drop from 2012. The FBI said in its annual Law Enforcement Officers Killed and Assaulted report that 49 died in accidents in 2013, while nearly 50,000 officers were assaulted while on duty. The 27 criminal deaths last year was down from 49 in 2012, 48 deaths in 2009 and 57 in 2004, according to the FBI. The deaths last year occurred in 16 states, and the average age of the officer killed was 39. ...
Exclusive: Pay per puff? Caffeine stick? E-cigarette boom sparks race for new...
24 Nov 2014 at 12:09pm
By Martinne Geller and Ben Hirschler LONDON (Reuters) - Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices. ...
U.N. to miss Dec 1 Ebola target due to rising Sierra Leone cases
24 Nov 2014 at 11:21am
By Matthew Mpoke Bigg ACCRA (Reuters) - The U.N. Ebola Emergency Response Mission will not fully meet its Dec. 1 target for containing the virus due to escalating numbers of cases in Sierra Leone, Anthony Banbury, the head of UNMEER, said on Monday. The mission set the goal in September of having 70 percent of Ebola patients under treatment and 70 percent of victims safely buried. That target will be achieved in some areas, Banbury told Reuters, citing progress in Liberia. "We are going to exceed the Dec 1 targets in some areas. But we are almost certainly going to fall short in others. ...
Little understood chemicals cut men?s fertility
24 Nov 2014 at 11:17am
By Ronnie Cohen (Reuters Health) ? A new study suggests that chemicals in sunscreen may impair men?s ability to father children, government scientists say. But other experts question whether the chemicals wound up in men?s urine from sunscreen or through another route. The FDA has not authorized the substances ? benzophenone-2, known as BP-2, and 4-hydroxybenzophenone, known as 4-OH-BP ? for use in sunscreens. BP-2 does show up as an ingredient in aftershaves, colognes, antiperspirant and other personal-care products. ...
HealthSouth buys home health operator as U.S. population ages
24 Nov 2014 at 11:05am
(Reuters) - Hospital operator HealthSouth Corp bought the owner of Encompass Home Health and Hospice, the latest deal in an industry that looks poised to grow as the U.S. population ages. HealthSouth, whose shares were up 3.8 percent at $39.72 in afternoon trading on Monday, said it was looking for further acquisitions in the fragmented sector. The company bought Encompass' owner, EHHI Holdings Inc, for about $750 million from healthcare-focused private investment firm Cressey & Co LP, expanding its home health business by adding 140 locations across 13 U.S. states. ...
'Dramatic improvement' in Ebola outlook in Liberia: U.S. general
24 Nov 2014 at 10:22am
By Emma Farge DAKAR (Reuters) - A U.S. general in the force helping Liberia fight the Ebola epidemic reported on Monday a dramatic improvement in the situation there and confirmed the cancellation of two planned treatment facilities. Brigadier General Frank Tate, deputy commanding general of U.S. Operation United Assistance, said the drop in the number of cases in the country was all the more encouraging given recent improvements in reporting capacity. He said new daily cases have fallen to around 20 from close to 80 when the operation was announced in September. ...